Emergent Biosolutions (NYSE:EBS) Stock: Insider Paul Anthony Williams Sells 3,000 Shares

Key Points

• Insider sale: Senior Vice President Paul Anthony Williams sold 3,000 Emergent BioSolutions shares at an average price of $6.53, totaling $19,590, under a pre-arranged Rule 10b5-1 plan. He retained 156,098 shares after the transaction.
• Stock performance: EBS traded at $6.72, with a market capitalization of approximately $344.6 million. The stock remains well below its 52-week high of $14.06 and has a negative price-to-earnings ratio.
• Analyst outlook: Wall Street’s consensus rating is Hold, with an average price target of $10.00. Recent ratings range from Buy to Sell, while institutional investors own 78.4% of the company.

Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) SVP Paul Williams sold 3,000 shares of the company's stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $6.53, for a total value of $19,590.00. Following the completion of the sale, the senior vice president owned 156,098 shares in the company, valued at $1,019,319.94. This represents a 1.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Emergent Biosolutions Stock Performance

Emergent Biosolutions stock traded up $0.39 during mid-day trading on Monday, hitting $6.72. 406,685 shares of the company's stock traded hands, compared to its average volume of 956,715. The stock has a market cap of $344.59 million, a price-to-earnings ratio of -1.91 and a beta of 2.28. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. The firm has a 50 day simple moving average of $6.11 and a two-hundred day simple moving average of $7.49. Emergent Biosolutions Inc. has a fifty-two week low of $4.36 and a fifty-two week high of $14.06.

Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.68. The firm had revenue of $234.30 million for the quarter, compared to analysts' expectations of $177.50 million. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. On average, research analysts expect that Emergent Biosolutions Inc. will post 0.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Weiss Ratings raised Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, August 21st. Zacks Research raised Emergent Biosolutions to a "hold" rating in a research report on Tuesday, August 11th. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Emergent Biosolutions in a research note on Friday, August 21st. They issued an "underweight" rating for the company. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $10.00.

Institutional Investors Weigh In On Emergent Biosolutions

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Emergent Biosolutions in the 2nd quarter worth approximately $39,525,000. Globeflex Capital L P bought a new position in shares of Emergent Biosolutions during the second quarter valued at about $2,022,000. Ancora Advisors LLC lifted its holdings in Emergent Biosolutions by 160.9% in the 2nd quarter. Ancora Advisors LLC now owns 1,067,867 shares of the biopharmaceutical company's stock worth $8,949,000 after buying an additional 658,600 shares during the period. Palisade Capital Management LP bought a new stake in Emergent Biosolutions in the second quarter valued at $4,316,000. Finally, Pacer Advisors Inc. purchased a new position in shares of Emergent Biosolutions during the first quarter valued at about $3,454,000. Institutional investors own 78.40% of the company's stock.

About Emergent Biosolutions

Emergent BioSolutions Inc NYSE: EBS is a life sciences company focused on developing, manufacturing and supplying medical countermeasures for public health threats, including chemical, biological, radiological and nuclear hazards, as well as infectious diseases. The company serves government agencies, healthcare providers and commercial customers.

Emergent's portfolio has included vaccines, therapeutics and other products used to prevent or treat serious health threats. Its offerings include BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine, along with products such as botulism antitoxin and vaccinia immune globulin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.